Clinical Trial

A Study to Assess Anktiva in Patients With Long Covid-19.

Study acronym: INTERRUPT_LC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-31; most recent amendment 2026-05-08.
Status change: Not Yet Recruiting → Recruiting 2026-03-24
Trial Details
NCT Number NCT07108036
Lead Sponsor ImmunityBio, Inc.
Conditions Long COVID
Enrollment 20 participants
Start Date 2025-11-14
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-11